Expertise in
20
conditions

Dr. Thomas E. Buekers

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Ascension St John Hospital
47601 Grand River Ave, Suite 2, 
Novi, MI 
Accepting New Patients
Expertise in
20
conditions
Ascension St John Hospital
47601 Grand River Ave, Suite 2, 
Novi, MI 
OverviewInsuranceLocationsClinical Research

Overview

Thomas Buekers is a Gynecologic Oncologist and an Oncologist in Novi, Michigan. Dr. Buekers is highly rated in 20 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Hysterectomy, and Oophorectomy. Dr. Buekers is currently accepting new patients.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in IA
Hospital Affiliations
Ascension St John Hospital
Henry Ford Health Hospital
Ascension Providence Hospital, Southfield And Novi
Henry Ford Health West Bloomfield Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Priority Health
  •  Blue Cross Blue Shield
  •  McLaren Health
  •  Humana

Locations

ASCENSION ST JOHN HOSPITAL
47601 Grand River Ave, Suite 2, Novi, MI 48374

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2025
Intervention Type: Biological
Study Phase: Phase 2
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2024
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

23 Total Publications

Ovarian cancer modulates the immunosuppressive function of CD11b+Gr1+ myeloid cells via glutamine metabolism.
Ovarian cancer modulates the immunosuppressive function of CD11b+Gr1+ myeloid cells via glutamine metabolism.
Journal: Molecular metabolism
Published: April 09, 2021
Similar Doctors
Expertise in
15
conditions
Dr. Ira S. Winer
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Expertise in
15
conditions
Dr. Ira S. Winer
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

University Physician Group

4100 John R St, 
Detroit, MI 
 (25.3 mi)
800-527-6266
Languages Spoken:
English, Hebrew
See accepted insurances
Accepting New Patients

Ira Winer is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Detroit, Michigan. Dr. Winer is highly rated in 15 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Vulvar Cancer, Vaginectomy, and Tubal Ligation. Dr. Winer is currently accepting new patients.

Expertise in
17
conditions
Dr. Michael L. Hicks
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
17
conditions
Dr. Michael L. Hicks
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
44405 Woodward Ave, Suite 202, 
Pontiac, MI 
 (15.2 mi)
248-858-2270
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Hicks is a Gynecologic Oncologist and an Oncologist in Pontiac, Michigan. Dr. Hicks is highly rated in 17 conditions, according to our data. His top areas of expertise are Cervical Cancer, Malignant Mixed Mullerian Tumor, Neuroendocrine Carcinoma of the Cervix, Hysterectomy, and Bladder Reconstruction. Dr. Hicks is currently accepting new patients.

Expertise in
25
conditions
Dr. Robert T. Morris
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
25
conditions
Dr. Robert T. Morris
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Ascension St John Hospital

22101 Moross Rd, 
Detroit, MI 
 (31.2 mi)
586-753-0011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Morris is a Gynecologic Oncologist and an Oncologist in Detroit, Michigan. Dr. Morris is highly rated in 25 conditions, according to our data. His top areas of expertise are Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, Malignant Mixed Mullerian Tumor, Oophorectomy, and Gastrostomy. Dr. Morris is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile